By Fineline Cube 
Eli Lilly & Co. (NYSE: LLY) today announced that its third‑quarter 2025 financial results exceeded expectations, posting a 54 % year‑over‑year (YoY) revenue increase to $17.60 billion. The growth was driven primarily by volume gains in its flagship GLP‑1/GIP metabolic portfolio, including tirzepatide (Mounjaro® and Zepbound®).
Key Financial Highlights
| Metric | Q3 2025 | YoY % | Q3 2025 vs Q2 2025 |
|---|---|---|---|
| Total Revenue | $17.60 B | +54 % | |
| US Revenue | $11.30 B | +45 % | |
| International Revenue | $6.30 B | +74 % | |
| Mounjaro Revenue | $6.52 B | +109 % | |
| Zepbound Revenue | $3.59 B | +185 % | |
| Verzenio Revenue | $1.47 B | +7 % |
- US Volume Growth – 60 % increase, offset by a 15 % decline in realized prices.
- International Volume Growth – 66 % increase; foreign‑exchange favorable by 6 %.
Strategic Implications
- Metabolic Focus – Mounjaro and Zepbound continue to dominate sales momentum, reinforcing Lilly’s leadership in type 2 diabetes and obesity therapeutics.
- Guidance Upgrade – The company now projects full‑year 2025 revenue of $63.0 B – $63.5 B, up from the $60.0 B – $62.0 B range previously set in Q2.
- Pipeline Confidence – Strong commercial performance supports ongoing investment in Lilly’s broader oncology and immunology pipelines.
Forward‑Looking Statements
This release contains forward‑looking statements that involve risks and uncertainties. Actual results may differ materially.-Fineline Info & Tech
Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidanceDownload